LAGUNA HILLS, Calif., Oct. 6 /PRNewswire/ — Minnow Medical,
Inc., a developer of a novel platform technology employing
radiofrequency thermoplasty for the treatment of in-stent
restenosis and other peripheral vascular conditions, announced
today the appointment of two veteran medical device executives.
Prabodh Mathur has been named chief product development officer
and Michael K. Handley has been named vice president of quality,
clinical and regulatory affairs.
“Both Prabodh and Michael are experts in their respective fields
and have the experience, drive and passion to assist Minnow in
executing the remaining clinical, regulatory and product
development activities necessary to gain clearance for the use of
our ZCath™ System to treat occlusions in the leg arteries of
patients with peripheral vascular disease,” said Raymond W. Cohen,
CEO of Minnow. “Minnow’s technology has already been proven to be
safe in human clinical studies in Europe. The goal of the new
management team is to become one of the first companies to
establish efficacy and gain U.S. Food and Drug Administration (FDA)
clearance to treat patients who have already received stent
implants in their peripheral leg arteries and are suffering from
in-stent restenosis – a dangerous build-up of plaque inside the
stents.”
About the Executives:Mathur is a seasoned technical executive
with a proven track record of developing complex, innovative, Class
III medical devices from concept, through design exploration, IP
review, engineering, manufacturing transfer, regulatory clearance
to market launch. Mathur held numerous engineering leadership
positions, including chief technical officer, with publicly traded
Cardiac Science over a 15-year period until 2009. Earlier, Mathur
was, for nine years, vice president engineering of Medstone
International, a manufacturer of transportable
lithotripters.
Over the past years, Mathur has been involved in developing
products incl
‘/>”/>
